Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized phase II trial of Lu-177 DOTATATE interval optimization in SSTr2-positive tumors (LUTHREE)
2015-004727-31Phase 2Terminated
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
- Start
- Sep 2019
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 2, randomised trial of lutetium Lu 177 dotatate in cancer (2 arms), sponsored by Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori". Primary endpoints: Progression-free survival and Disease control rate. Started Sep 2019; status: terminated.
02
Drugs
lutetium Lu 177 dotatate
03
Conditions
cancer
Beyond the preview
Go deeper on 2015-004727-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004727-31.